Actively Recruiting

Phase 4
Age: 18Years - 55Years
FEMALE
NCT07295054

3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

Led by Women's College Hospital · Updated on 2026-05-11

110

Participants Needed

1

Research Sites

40 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.

CONDITIONS

Official Title

3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

Who Can Participate

Age: 18Years - 55Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a uterus
  • Ages 18 to 55 years
  • Undergoing any intrauterine device (IUD) insertion
  • English-speaking participants
  • Ability to use an inhaler device
  • Willing to receive a cervical block for their IUD insertion
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Confirmed pregnancy
  • Use of pain medication other than NSAIDs or acetaminophen within 24 hours prior to intervention
  • Use of cannabis within 24 hours prior to intervention
  • Administration of misoprostol within 24 hours prior to intervention
  • Altered level of consciousness from any cause
  • History of severe reactions to Penthrox (methoxyflurane) or similar anesthetic agents
  • Anatomical variance such as distorted uterine cavity, bicornuate uterus, uterus didelphys, or cervical stenosis
  • Clinically significant kidney or liver impairment
  • Known or genetic susceptibility to malignant hyperthermia
  • Clinically evident hemodynamic or cardiovascular instability, or respiratory depression
  • Not NPO according to hospital guidelines

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Women's College Hospital

Toronto, Ontario, Canada, M5S 1B2

Actively Recruiting

Loading map...

Research Team

D

Didem Bozak

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here